UDENYCA, a biosimilar to Neulasta (pegfilgrastim), significantly expands Intas and Accord’s FDA-approved biosimilar portfolio
Intas Pharmaceuticals, in collaboration with its global subsidiaries operating under the Accord brand, has solidified its position as one of the world’s leading suppliers of pegfilgrastim following the successful acquisition of UDENYCA (pegfilgrastim-cbqv) from Coherus BioSciences, Inc.
UDENYCA, a biosimilar to Neulasta (pegfilgrastim), significantly expands Intas and Accord’s FDA-approved biosimilar portfolio, accelerating their strategic growth in the global biosimilar market. The acquisition further strengthens the company’s presence and impact in both the US and international biosimilar landscapes.
With the acquisition, Accord BioPharma, the US specialty business of Intas, continues the commercialisation of UDENYCA to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. UDENYCA offers three patient-friendly administration options—autoinjector (AI), on-body injector (OBI), and prefilled syringe (PFS)—providing flexibility for treatment at home, on-the-go, or in clinical settings. Since its commercial launch, over 300,000 patients have been treated with UDENYCA and more than 1.4 million units have been distributed.
Binish Chudgar, CMD, Intas Pharmaceuticals, said, “We are energised by this addition to Accord BioPharma’s portfolio because it exemplifies our commitment to improving patient access to high-quality treatments that meet the evolving needs of both patients and healthcare providers. This acquisition cements our position as a global leader in pegfilgrastim and allows us to further expand our speciality division across key international markets.”
Chrys Kokino, US President, Accord BioPharma, commented,
“The completion of the UDENYCA acquisition marks a pivotal moment for Accord BioPharma, as it not only strengthens our market presence but broadens our capabilities as we endeavour to innovate and expand in the biosimilar space.”
Paul Tredwell, EMENA Executive Vice-President of Accord, said, “With the Accord Biopharma team now fully commercialising UDENYCA in three different formulations, this development strengthens Accord’s offering and advances our goal of becoming the world’s leading supplier of pegfilgrastim.”
